NodThera has developed first-in-class small-molecule inhibitors of the NLRP3 inflammasome, a master switch for inflammation, and is charting a clinical path to patients in multiple indications. Many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback